Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose

The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outco...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2017-07, Vol.58 (7), p.1589-1597
Main Authors: Bond, David A., Huang, Ying, Ruppert, Amy S., Walker, Alison R., Dotson, Emily K., Roddy, Julianna, Blum, Kristie A., Christian, Beth A.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bendamustine
Bendamustine Hydrochloride - administration & dosage
Female
Humans
immunotherapeutic approaches
Kaplan-Meier Estimate
lymphoma and Hodgkin disease
Lymphoma, Mantle-Cell - diagnosis
Lymphoma, Mantle-Cell - drug therapy
Lymphoma, Mantle-Cell - mortality
Male
Middle Aged
Neoplasm Staging
Odds Ratio
Proportional Hazards Models
Retrospective Studies
Rituximab - administration & dosage
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/m 2 . Lower starting dosage (
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2016.1253835